Novel tau degradation strategies—including proteolysis-targeting chimeras (PROTACs) and nanobody-enabled aggregation disruptors—demonstrate selective clearance of pathological tau, including hyperphosphorylated, misfolded, and aggregation-prone tau species associated with NFTs, in preclinical models [32]. The gene discussed is MAPT; the disease is Neurofibrillary tangles.